multiple sclerosis Flashcards

1
Q

what is multiple sclerosis?

A
  • chronic, inflammatory demyelinating and neurodegenerative disease of the central nervous system
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the 3 types of disease that MS is described?

A
  • heterogenous
  • multifactorial
  • immune mediated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is multiple sclerosis caused by?

A
  • caused by complex gene- environment interaction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is the pathological hallmark of MS?

A
  • accumulation of demyelinating lesions that occur in the brain and spinal cord’s white and gray matter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what does multiple sclerosis not affect?

A
  • doesn’t affect the PNS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is the estimated prevalence of MS in Europe for the past three decades?

A
  • 83 per 100,000
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what gender are more likely to develop multiple sclerosis?

A
  • females
  • female: male ratio is around 2:0
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what countries have higher rates of multiple sclerosis?

A
  • Northern countries
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

how many people live with MS in Europe?

A
  • more than 1,000
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is the percentage increase of people living with MS over the last 3 years?

A
  • more than 35% increase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the estimation of the number of MS individuals in the UK?

A
  • over 130,000 people
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

how many people are newly diagnosed with MS each year in the UK?

A
  • nearly 7,000 people are newly diagnosed each year
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what percentage of MS individuals are women?

A
  • 73%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are the 4 primary disease courses of multiple sclerosis?

A
  • clinically isolated syndrome
  • relapsing- remitting MS
  • secondary progressive MS
  • radiologically isolated syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what does clinically isolated syndrome refer to?

A
  • refers to the first episode of neurological symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is clinically isolated syndrome caused by?

A
  • caused by inflammation and demyelination in the CNS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

how long must the episode last in clinically isolated syndrome?

A
  • must last at least 24 hours
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what is the relation of CIS to MS?

A
  • CIS can be a precursor to MS
  • but not all individuals with CIS go onto developing MS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

how does an MRI show an increased likelihood of person progressing from CIS to MS?

A
  • MRI showing brain lesions similar to those in MS increases the likelihood of progression to MS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what are the common symptoms of clinically isolated syndrome? (3)

A
  • headaches
  • gait problems
  • verbal disturbances
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what is the most common disease course?

A
  • relapsing remitting MS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what is relapsing- remitting multiple sclerosis characterised by?

A
  • characterised by clearly defined attacks of new or increasing neurological symptoms (relapses) followed by periods of partial or complete recovery (remissions)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what percent of MS patients are initially diagnosed with RRMS?

A
  • 85% are initially diagnosed with RRMS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

does the disease progress in the remission phase?

A
  • disease does not appear to progress during the remission phase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

how is relapsing- remitting multiple sclerosis modulated?

A
  • modulated through medication
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

what is secondary progressive multiple sclerosis?

A
  • neurological function worsens
  • disability accumulates from the onset of symptoms without early relapses or remissions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

how many people with MS are diagnosed with SPMS?

A
  • about 15%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

what is the hardly recognised course of MS?

A
  • radiologically isolated syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

what is RIS used for?

A
  • used to classify individuals with MRI- detected brain or spinal cord lesions consistent with MS but without past or current neurological symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

what does a graph showing progressive relapsing MS show?

A
  • shows steady decline since onset with super- imposed attacks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

what does a graph of secondary progressive MS show?

A
  • initial relapsing remitting multiple sclerosis that suddenly begins to decline without periods of remissions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

what does a graph of primary progressive MS show?

A
  • steady increase in disability without attacks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

what does a graph of relapsing- remitting multiple sclerosis show?

A
  • unpredictable attacks which may or may not leave permanent deficits followed by periods of remission
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

what are the three prominent pathological features of progressive multiple sclerosis?

A
  • global brain atrophy
  • slowly expanding lesions
  • predominantly microglia/ macrophage- mediated inflammatory response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

what is neurodegeneration in MS driven by?

A
  • driven by complex interplay between compartmentalised neuroinflammation, oxidative stress, iron toxicity and mitochondrial dysfunction
36
Q

when does neurodegeneration in MS occur?

A
  • occurs as early as the radiologically and clinically isolated syndrome starts
37
Q

what do CNS injuries have the potential to do?

A
  • potential to affect everything
38
Q

what does MS specifically affect? (2)

A
  • optic nerve
  • any tissue within the brain and spinal cord
39
Q

what are the symptoms like in people with MS ?

A
  • widespread
  • heterogenous (different across multiple individuals)
40
Q

what are the 11 common symptoms of multiple sclerosis?

A
  • fatigue
  • weakness
  • spasticity
  • sensory impairments
  • pain
  • bladder dysfunction
  • disorders of emotions
  • tremors
  • incoordination or ataxia
  • dysarthria
  • dysphasia
41
Q

what does a clinical assessment for MS involve? (2)

A
  • neurological examination
  • medical history
42
Q

what is signs of neurological impairment and history of symptoms suggestive of?

A
  • suggestive of CNS involvement
43
Q

what is the most sensitive non- invasive test for detecting MS- related brain and spinal cord changes?

A
  • magnetic resonance imaging
44
Q

what does MRI help with?

A
  • helps to identify lesions/ scars (sclerosis) typical of MS
45
Q

what does CSF stand for?

A
  • cerebrospinal fluid
46
Q

what dos CSF analysis involve?

A
  • lumbar puncture (spinal tap)
47
Q

what do you analyse from the lumbar puncture?

A
  • presence of oligoclonal bands (unique proteins) in the CSF, which are not found in the blood supports the diagnosis of MS
48
Q

what is an evoked potential test?

A
  • test that measures the brain’s electrical activity in response to stimuli
49
Q

what can evoked potential tests detect?

A
  • can detect demyelinated lesions along nerve pathways that are too small or in locations not detected by MRI
50
Q

what is the point in blood tests when diagnosing MS?

A
  • important to rule out other diseases with similar symptoms e.g., lyme disease or certain autoimmune disorders
51
Q

what does the McDonald Criteria integrate?

A
  • clinical presentation with MRI findings
52
Q

what did the 2017 revision of the McDonald Criteria allow for?

A
  • earlier and more accurate diagnosis by incorporating specific MRI criteria that can substitute for a clinical relapse in determining disease dissemination in time
53
Q

what are the two main things that the McDonald criteria involves?

A
  • dissemination in space and time
54
Q

what does dissemination in space refer to?

A
  • how the lesions evolve across structures
55
Q

what does dissemination in time refer to?

A
  • how the lesions progress in time
56
Q

what are the two outcome measures used to measure disease severity?

A
  • functional systems score (FSS)
  • expanded disability status scale (EDSS)
57
Q

what are the three main medical management of multiple sclerosis?

A
  • disease modifying therapies
  • management of acute relapses
  • symptomatic treatment
58
Q

what do disease modifying therapies reduce?

A
  • reduce relapsing frequency and severity
  • slow disability progression
  • limit new disease activity
59
Q

what are some examples of drugs used in disease modifying therapies?

A
  • interferon beta preparations
  • glatiramer acetate
  • natalizumab
  • figolimod
  • ocrelizumab
  • cladribine
60
Q

what does the choice of DMT depend on? (4)

A
  • disease course
  • drug effectiveness
  • side effects
  • patient preferences
61
Q

how do you manage acute relapses?

A
  • anti- inflammatory medications
  • high dose corticosteroids
  • plasmapheresis
62
Q

what are exacerbations of MS usually treated with?

A
  • usually treated with high- dose corticosteroids such as intravenous methylprednisolone
63
Q

what does symptomatic treatment involve?

A
  • pharmacological and non- pharmacological treatments including medication and therapy
64
Q

what impairments are assessed in multiple sclerosis? (5)

A
  • fatigue
  • cognition
  • balance
  • gait
  • upper extremity
65
Q

how do you assess fatigue?

A
  • modified fatigue impact scale (MFIS)
  • fatigue scale for motor and cognitive function
66
Q

what are the common cognitive deficits? (7)

A
  • learning
  • memory
  • information processing speed
  • executive function
  • planning
  • organisation
  • initiation
67
Q

how do you assess cognition?

A
  • paced auditory serial addition test (PASAT)
68
Q

how do you assess balance?

A
  • anticipatory response challenges and reactive balance strategies
  • perturbation response
  • BESTest
  • miniBESTest
  • TUG
  • BBS
69
Q

how do you assess gait?

A
  • speed
  • distance
  • quality (observation gait)
  • gait cycle
  • step length
  • step width
  • cadence
  • single- leg support
  • double- leg support
  • 6MWT
  • TUG
70
Q

how do you assess upper extremity?

A
  • box and blest test (BBT)
  • nine hole peg test (NHPT)
71
Q

how do you manage fatigue?

A
  • energy conservation programs show strong evidence for managing MS- related fatigue
72
Q

what rehabilitation interventions manages fatigue in neurological conditions? (3)

A
  • physical activity
  • cognitive education programs
  • energy conservation strategies
73
Q

what are sensory interventions to manage fatigue? (3)

A
  • vestibular rehabilitation
  • exercise - based sensory integration interventions
  • vibration
74
Q

what shows the most promising intervention for treating fatigue?

A
  • balance exercises
  • cognitive behavioural therapies
75
Q

what medical management is used for spasticity?

A
  • antispasticity medications
  • baclofen
  • tizanidine
  • gasapentin
  • dantrolene
  • tolperisone
  • benzodiazepines
  • sativex oromucosal spray
76
Q

what may be required in selected cases for the medical management of spasticity?

A
  • botulinum toxin
  • intrathecal baclofen
77
Q

what interventions can be used for spasticity?

A
  • ROM
  • stretching
  • orthotics (braces and splints)
78
Q

how do you manage pain? (6)

A
  • pharmacological management
  • posture
  • movement
  • sitting
  • orthotics
  • supportive equipment/ adaptive equipment
79
Q

what do balance exercises prevent and enhance?

A
  • prevents falls and enhance walking stability and posture control
80
Q

what are the benefits of coordination exercises?

A
  • reduces energy requirements
  • increases continuity of movement
81
Q

what are Frenkel exercises improve? what does it involve?

A
  • improve movement coordination
  • involves slow repetitions of each movement stage, gradually increasing in complexity
82
Q

what are the three phases of sitting up?

A
  • withdrawing feet
  • bending trunk forwards
  • straightening legs while getting
83
Q

what are some balance exercises?

A
  • balance based torso weighting
  • balance and eye- movement exercises in persons with MS
84
Q

what should you consider balance in?

A
  • consider balance in different postural settings
  • sitting, wheelchair use, walking aid
85
Q

what is the main management of balance?

A
  • core stability exercises
  • task oriented training
  • conventional balance training
  • effectively improve balance in ataxic MS patients
86
Q

what are the 6 interventions for balance?

A
  • mobility
  • aerobic and strength training
  • task specific training
  • torso weighting
  • mobility assistive devices
  • orthotics